Original Research Article|Articles in Press

High-volume centers are associated with higher receipt of combined therapy in stage III pancreatic cancer

Published:February 21, 2023DOI:


      • Chemotherapy and surgical resection improve survival in stage III PDAC.
      • Patients diagnosed at high-volume centers are more likely to receive combined chemotherapy and surgical resection.
      • Diagnosis at a high-volume center, later year of diagnosis, and younger age are associated with receipt of combined therapy.



      Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at a locally advanced stage with vascular involvement which was previously viewed as a contraindication to resection. However, high-volume centers are increasingly capable of resecting complex tumors. We aimed to explore patterns of treatment that are uncharacterized on a population level.


      A statewide registry was queried from 2003 to 2018 for stage III PDAC. Stepwise logistic regression and Kaplan-Meier were used for statistical analysis.


      We identified 424 eligible patients. 348 (82%) received chemotherapy, 17 (4.0%) received resection, and 59 (13.9%) received both; median survival was 10.7, 8.7, and 22.7 months, respectively (P < 0.001). High-volume centers (≥20 cases per year; OR 5.40 [95% CI: 2.76, 10.58], P < 0.001) and later year of diagnosis (OR 1.12/year [95% CI: 1.04, 1.20], P = 0.004) were associated with higher odds of receiving combined therapy.


      PDAC patients with vascular involvement who receive both systemic chemotherapy and surgical resection have improved overall survival. High-volume centers are independently associated with higher odds of receiving combined systemic therapy and surgical resection.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chopra A.
        • Hodges J.C.
        • Olson A.
        • et al.
        Outcomes of neoadjuvant chemotherapy versus chemoradiation in localized pancreatic cancer: a case-control matched analysis.
        Ann Surg Oncol. Jul 2021; 28: 3779-3788
        • Machairas N.
        • Raptis D.A.
        • Velázquez P.S.
        • et al.
        The impact of neoadjuvant treatment on survival in patients undergoing pancreatoduodenectomy with concomitant portomesenteric venous resection: an international multicenter analysis.
        Ann Surg. Nov 1. 2021; 274: 721-728
        • Moaven O.
        • Clark C.
        • Russell G.
        • et al.
        Treatment patterns and outcomes in resected pancreatic cancers: frequent deviations from standard of care.
        HPB. 2020; 22: S91-S92
        • Maggino L.
        • Malleo G.
        • Marchegiani G.
        • et al.
        Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma.
        JAMA Surgical resection. 2019; 154: 932-942
        • Versteijne E.
        • Suker M.
        • Groothuis K.
        • et al.
        Preoperative chemoradiotherapy versus immediate surgical resection for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial.
        J Clin Oncol. Jun 1 2020; 38: 1763-1773
        • Tempero M.A.
        • Malafa M.P.
        • Al-Hawary M.
        • et al.
        Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology.
        J Natl Compr Cancer Netw. Apr 1 2021; 19: 439-457
        • Lidsky M.E.
        • Sun Z.
        • Nussbaum D.P.
        • Adam M.A.
        • Speicher P.J.
        • Blazer 3rd, D.G.
        Going the extra mile: improved survival for pancreatic cancer patients traveling to high-volume centers.
        Ann Surg. Aug 2017; 266: 333-338
        • Rhodin K.E.
        • Raman V.
        • Jensen C.W.
        • et al.
        The effect of center esophagectomy volume on outcomes in clinical stage I-III esophageal cancer.
        Ann Surg. Aug 30 2022;
        • Fong Y.
        • Gonen M.
        • Rubin D.
        • Radzyner M.
        • Brennan M.F.
        Long-term survival is superior after resection for cancer in high-volume centers.
        Ann Surg. Oct 2005; 242 (; discussion 544-7): 540-544
        • Guilbaud T.
        • Turrini O.
        • Lemoine C.
        • et al.
        Venous resection in pancreatic ductal adenocarcinoma: impact of surgical experience on early postoperative courses.
        Anticancer Res. Aug 2017; 37: 4205-4213
        • Ahola R.
        • Siiki A.
        • Vasama K.
        • Vornanen M.
        • Sand J.
        • Laukkarinen J.
        Effect of centralization on long-term survival after resection of pancreatic ductal adenocarcinoma.
        Br J Surg. Oct 2017; 104: 1532-1538
        • Briceno P.
        • Huston J.
        • Shridhar R.
        • Meredith K.
        Pancreatic resection at high volume centers improves survival.
        HPB. 2017; 19: S171
        • Kutlu O.C.
        • Vega E.A.
        • Salehi O.
        • et al.
        Laparoscopic pancreatectomy for cancer in high volume centers is associated with an increased use and fewer delays of adjuvant chemotherapy.
        HPB. 2021; 23: 625-632
        • MacKinney E.C.
        • Holoubek S.A.
        • Khokar A.M.
        • et al.
        Treatment differences at high volume centers and low volume centers in non-metastatic and metastatic adrenocortical carcinoma.
        Am J Surg Resect. 2022/03/01/2022; 223: 582-586
        • Hsu D.S.
        • Kumar N.S.
        • Le S.T.
        • et al.
        Centralization of pancreatic cancer treatment within an integrated healthcare system improves overall survival.
        Am J Surg. Jun 2022; 223: 1035-1039
        • Tseng J.F.
        • Raut C.P.
        • Lee J.E.
        • et al.
        Pancreaticoduodenectomy with vascular resection: margin status and survival duration.
        J Gastrointest Surg. Dec 2004; 8 (; discussion 949-50): 935-949
        • Abdel-Rahman O.
        • Xu Y.
        • Tang P.A.
        • Lee-Ying R.M.
        • Cheung W.Y.
        A real-world, population-based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer.
        Cancer Med. Dec 2018; 7: 6385-6392
        • Chang D.C.
        • Zhang Y.
        • Mukherjee D.
        • et al.
        Variations in referral patterns to high-volume centers for pancreatic cancer.
        J Am Coll Surg. Dec 2009; 209: 720-726
        • Sgroi M.D.
        • Narayan R.R.
        • Lane J.S.
        • et al.
        Vascular reconstruction plays an important role in the treatment of pancreatic adenocarcinoma.
        J Vasc Surg. Feb 2015; 61: 475-480
        • Ravikumar R.
        • Sabin C.
        • Abu Hilal M.
        • et al.
        Portal vein resection in borderline resectable pancreatic cancer: a United Kingdom multicenter study.
        J Am Coll Surg. Mar 2014; 218: 401-411
        • Marsoner K.
        • Langeder R.
        • Csengeri D.
        • Sodeck G.
        • Mischinger H.J.
        • Kornprat P.
        Portal vein resection in advanced pancreatic adenocarcinoma: is it worth the risk?.
        Wien Klin Wochenschr. Aug 2016; 128: 566-572
        • Sutton T.L.
        • Beneville B.
        • Johnson A.J.
        • Mayo S.C.
        • Gilbert E.W.
        • Lopez C.D.
        • Grossberg A.J.
        • Rocha F.G.
        • Sheppard B.C.
        Socioeconomic and geographic disparities in the referral and treatment of pancreatic cancer at high-volume centers.
        JAMA surgery. 2022; (Advance online publication)e226709